Establishment of Biobank and Patient-Derived Xenograft of Soft Tissue and Bone Tumors.

Autor:	Okada S; Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, JPN., Boonnate P; Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, JPN.; Laboratory of Environmental Toxicology, Chulabhorn Research Institute, Bangkok, THA., Panaampon J; Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, JPN.; Division of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA., Saisuwan K; Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, JPN., Ogata-Aoki H; Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, JPN., Abe M; Division of Diagnostic Pathology, Tochigi Cancer Center, Utsunomiya, JPN., Hirabayashi K; Division of Diagnostic Pathology, Tochigi Cancer Center, Utsunomiya, JPN., Nakagawa R; Division of Musculoskeletal Oncology and Orthopaedics Surgery, Tochigi Cancer Center, Utsunomiya, JPN., Kikuta K; Division of Musculoskeletal Oncology and Orthopaedics Surgery, Tochigi Cancer Center, Utsunomiya, JPN.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Nov 29; Vol. 16 (11), pp. e74781. Date of Electronic Publication: 2024 Nov 29 (Print Publication: 2024).
DOI:	10.7759/cureus.74781
Abstrakt:	Soft tissue and bone tumors are rare, and their low frequency and diverse histological types make conducting large-scale clinical trials challenging. Patient-derived xenografts (PDX), entailing implantation of cancer specimens in immunocompromised mice, are emerging as a valuable translational model because PDX keeps the original tumors' character and drug sensitivity. We sequentially transplanted 166 surgical and biopsy specimens from orthopedic surgeries, including 138 soft tissue and bone tumors (81 malignant, 23 intermediate, and 34 benign), 16 metastatic bone tumors, 9 hematological malignancies, and 3 non-tumor tissues. Every specimen was cutaneously transplanted into both flanks of BALB/c Rag-2/Jak3 double deficient (BRJ) mice, and tumor formation was observed for up to 6 months. We defined PDX models as successfully generated if the tumors were passaged more than three times while retaining the histological characteristics of the original tumor. The rates of PDX generation were 28.1% (39/138) for all soft tissue and bone tumors, 42.6% (35/81) for malignant tumors, 4.3% (1/23) for intermediate tumors, and 8.8% (3/34) for benign tumors. Our models of PDX would be a useful platform for soft tissue and bone tumor precision medicine. Competing Interests: Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Ethics Committee of Tochigi Cancer Center issued approval 30-78-20-20201119 on November 19, 2020. Animal subjects: Kumamoto University Animal Ethics Committee Issued protocol number A2021-052 (1 April 2021), A2019-020 (1 April 2019). Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: This research was funded by the Strategic Core Technology Advancement Program from the Ministry of Economy, Trade and Industry, Japan. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Okada et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu